← Eichor
Condition: Pancreatic Adenocarcinoma Non Resectable Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pancreatic Adenocarcinoma Non Resectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
NA · 2 location(s) · Alpha Tau Medical LTD. · NCT05657743Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Chang
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05372614A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Phase 2 · 1 location(s) · University of Pennsylvania · NCT07199764Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pa
Phase 2 · 26 location(s) · Endevica Bio · NCT06937177Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
NA · 2 location(s) · BetaGlue Therapeutics SpA · NCT07155850A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NA · 1 location(s) · Fox Chase Cancer Center · NCT06984562A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advance
Phase 1/Phase 2 · 85 location(s) · GlaxoSmithKline · NCT06885034CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
Phase 1 · 1 location(s) · John Lenehan · NCT06393400Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
Phase 1 · 2 location(s) · Impact Biotech Ltd · NCT05919238A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06261359Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NA · 15 location(s) · Alpha Tau Medical LTD. · NCT06698458Surgery for Locally Unresectable Pancreatic Cancer
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07241663CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Phase N/A · 1 location(s) · Fujian Provincial Hospital · NCT06643208PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
Phase 1 · 1 location(s) · University of California, Irvine · NCT07549958High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05053555Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Phase 1/Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT04789486Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · 4 location(s) · Proton Collaborative Group · NCT02598349Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1 · 18 location(s) · AstraZeneca · NCT06218914A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 · 3 location(s) · Boehringer Ingelheim · NCT06882746A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.